ASweetLife – Nanoparticles May Be Used to Treat Type 1 Diabetes

“A couple of weeks ago I sat down with Dr. Francisco Quintana, who runs a lab at Brigham and Women’s Hospital in Boston focused on finding new treatments for autoimmune diseases. In particular, he’s working on developing nanoparticles that would address the autoimmune attack on islet cells that characterizes type 1 diabetes. JDRF has been funding Dr. Quintana’s work in the lab since 2011, and in September it joined with Pfizer and a venture capital firm to fund a biotech start-up called AnTolRx, which will seek to bring targeted nanoparticle tolerance therapeutics (TNTT) to market, to treat type 1 diabetes and a range of other auto-immune disorders. According to Dr. Peter Lomedico, JDRF’s director of research business development, this venture is the first time that JDRF has invested in an academic project and then in a company designed to bring that project to market.”… Read More